• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
    • News & Updates
  • Donate
Home / Ask the Expert / Effectiveness of treatment and insurance issues?

Effectiveness of treatment and insurance issues?

August 1, 2007 By Arthritis Center

Question

Kindly answer the following questions 1-I have taken 2 in infusions of remicade, third loading dose which was to be a month apart after second dose has been delayed due to an infection. I have no relief. I have problems with my insurance company, as they do not believe that the medicine is not affective on me. Are there tests which can indicate the affectivness of remicade 2-Secondly what alternate medicines are avilable, incase remicade does not continue to be affective, 3-Also please let me know if remicade works for me, will I have to stay on it LIFE LONG or at some point on can be off this drug, as I plan to move out of my present country of residence in few years and country I plan to go I would not be able to afford this medicine.

Answer

These are good questions.  Increasingly, insurers are requiring proof that biologic drugs are working.  There are scoring methods for RA disease activity designed for use in clinical trials.  They are called the DAS and the ACR response criteria, and are a score calculated from the combination of the number of swollen and tender joints, pain questionaires and inflammatory markers in the blood (ESR and CRP).  Drugs like Remicade, Enbrel and Humira often need to be continued indefinitely as long as the RA remains active.  Since RA is considered a chronic disease, this could potentially mean life-long.  The traditional DMARDs, methotrexate, hydroxychloroquine, sulfasalazine, leflunomide might be used alone or in combination in place of the biologic agents.

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Primary Sidebar

Ask The Expert Topics

  • Alternative Therapies
  • Ankylosing Spondylitis
  • Associated With Other Illnesses
  • Bursitis and Tendinitis
  • Corticosteroids
  • Diet and Exercise
  • Disease Modifying Antirheumatic Drugs (DMARDs)
  • Enteropathic Arthritis
  • Fibromyalgia
  • General Arthritis
  • Gout, Pseudogout, Other
  • Infectious Arthritis
  • Myositis
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Osteoarthritis
  • Osteonecrosis
  • Osteoporosis
  • Polymyalgia Rheumatica
  • Psoriatic Arthritis
  • Reactive Arthritis
  • Regional Pain: Back and Neck
  • Rehabilitation
  • Rheumatoid Arthritis
  • Surgical Therapy
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis
  • Vasculitis
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2025 Johns Hopkins Arthritis Center
Patient Privacy